New scan could reveal hidden cancer cells

NCT ID NCT05620472

Completed Diagnosis Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tested a radioactive imaging agent called [99mTc]Tc(CO)3-(HE)3-Ec1 in 10 adults with solid tumors. The agent is designed to attach to EpCAM receptors on cancer cells, making them visible on SPECT scans. Researchers aimed to see where the agent goes in the body, measure radiation exposure, and check safety. This is a diagnostic study, not a treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: [99mTc]Tc(CO)3-(HE)3-Ec1 (a radioactive imaging agent)
What this could lead to: If successful, this could lead to a new way to see certain cancer cells on scans, helping doctors diagnose or monitor tumors more precisely.
What could go wrong: This is a very small, early Phase 1 study with only 10 participants. It is designed to test safety and imaging, not treatment. The approach may not prove useful for routine care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMOR, ADULT

Contacts and locations

Locations

TomskNRMC

Tomsk, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.